Evaxion Biotech A/S (EVAX)
| Market Cap | 40.98M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -23.17M |
| Shares Out | 26.44M |
| EPS (ttm) | -0.98 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 94,728 |
| Open | 1.59 |
| Previous Close | 1.59 |
| Day's Range | 1.49 - 1.61 |
| 52-Week Range | 0.92 - 3.52 |
| Beta | 0.58 |
| Analysts | Strong Buy |
| Price Target | 9.00 (+480.65%) |
| Earnings Date | Jun 6, 2023 |
About EVAX
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-c... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for EVAX stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 480.65% from the latest price.
News
Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01
COPENHAGEN, Denmark, May 25, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powe...
Evaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccines
COPENHAGEN, Denmark, May 25, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and developm...
Evaxion to host R&D Day on May 25, 2023
COPENHAGEN, Denmark, May 16, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and developm...
Fourth quarter and full year 2022 financial results and business update
COPENHAGEN, Denmark, April 27, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-dr...
Evaxion announces promising clinical data for DNA-based personalized cancer immunotherapy EVX-02: Phase 1/2a trial met both primary and secondary endpoints
COPENHAGEN, Denmark, April 18, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-po...
Evaxion and Pennsylvania State University publish preclinical data validating our AI-based viral vaccine discovery platform
COPENHAGEN, Denmark, April 13, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in AI-powered immunotherapies, announces the successful ...
Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients
COPENHAGEN, Denmark, March 28, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and develo...
Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients
COPENHAGEN, Denmark, March 23, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and develo...
Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)
COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-po...
Evaxion and Pantherna announce promising preclinical mRNA vaccine data
COPENHAGEN, Denmark and HENNIGSDORF, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in ...
Evaxion receives FDA fast-track designation for personalized cancer immunotherapy
COPENHAGEN, Denmark, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-dri...
Evaxion's stock soars after getting FDA approval for mid-stage cancer trial
U.S.-listed shares of Evaxion Biotech A/S EVAX, +0.47% jumped about 17% in premarket trading on Tuesday after the company said the Food and Drug Administration has allowed a Phase 2b clinical trial te...
Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01
COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-dri...
Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023
COPENHAGEN, Denmark, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-dri...
Evaxion and ExpreS²ion initiate research collaboration on a novel cytomegalovirus (CMV) vaccine candidate
HØRSHOLM, Denmark, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-drive...
Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02
COPENHAGEN, Denmark, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-dri...
Evaxion Announces Third Quarter 2022 Financial Results and Business Update
COPENHAGEN, Denmark, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company), a clinical-stage biotechnology company specializing in the development of AI-driv...
Evaxion CEO comments on strategic focus
COPENHAGEN, Denmark, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-dri...
Evaxion welcomes Per Norlén as new CEO.
COPENHAGEN, Denmark, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-dri...
Important Milestone Reached for Evaxion Biotech's EVX-01 Personalized Cancer Therapy
COPENHAGEN, Denmark, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-dr...
Evaxion Announces NIH Grant for Research Collaboration With UMass Chan Medical School
COPENHAGEN, Denmark, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), announced today that the Company, in collaboration with UMass Chan Medical Scho...
Evaxion Biotech Announces Second Quarter 2022 Financial Results and Provides Business Update
COPENHAGEN, Denmark, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-dri...
Evaxion Biotech A/S Announces Executive Management Changes
COPENHAGEN, Denmark, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-dri...
Evaxion Biotech to Host Q2 2022 Corporate Update Conference Call & Webcast on August 10
COPENHAGEN, Denmark, July 29, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-dri...
Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target
COPENHAGEN, Denmark, June 30, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-dri...